Dantrolene sodium hemiheptahydrate (Agilus®). HTA ID: 24016

Assessment Status Rapid Review complete
HTA ID 24016
Drug Dantrolene sodium hemiheptahydrate
Brand Agilus®
Indication In combination with adequate support measures, dantrolene sodium hemiheptahydrate is indicated for the treatment of malignant hyperthermia in adults and children of all ages.
Assessment Process
Rapid review commissioned 20/05/2024
Rapid review completed 27/06/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that dantrolene sodium hemiheptahydrate (Agilus®) not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.